2015 Archive:
ASX Announcements and News Releases

11/02/2015

Half Year Result 2015

CSL Limited (ASX:CSL; USOTC:CSLLY) today announced a net profit after tax (NPAT) of US$692 million for the six months ended 31 December 2014, up US$47 million or 7% on a reported basis when compared to the prior comparable period (PCP). Earnings per share (EPS) grew 10%.

23/04/2015

Gordon Naylor to lead CSL's Global Influenza Vaccine Business

CSL Limited (ASX:CSL; USOTC:CSLLY) – CSL today announced that Gordon Naylor will lead CSL's new global influenza vaccine business, which is planned for launch at the start of 2016.

15/06/2015

Tax Competitiveness for Advanced Manufacturing the key to commercialising Australian R&D

A more competitive corporate tax rate would enable Australia to attract valuable investment in advanced manufacturing and in turn convert its world leading R&D into fully-fledged industries located in Australia, according to CSL Limited, Australia's largest biotechnology company.

17/06/2015

CSL Behring to Present Pivotal Data for rVIII-SingleChain and rIX-FP at ISTH Congress

CSL Limited (ASX:CSL; USOTC:CSLLY) today announced that CSL Behring will present more than 20 abstracts, including five oral presentations, from across its hematology portfolio of investigational and branded products at the 2015 International Society on Thrombosis and Haemostasis (ISTH) Congress being held in Toronto June 20 through 25.

18/06/2015

CSL Aquires Exclusive Rights to Influenza Treatment

CSL Limited (ASX:CSL) today announced it has acquired exclusive rights to commercialise the influenza treatment, RAPIVAB®, from US-based company, BioCryst Pharmaceuticals Inc (NASDAQ: BCRX).

28/07/2015

U.S. FDA Accepts for Review CSL Behring's BLA for its Novel rVIII-SingleChain Therapy for Patients with Haemophilia A

CSL Limited (ASX:CSL; USOTC: CSLLY) announced today that the U.S. Food and Drug Administration (FDA) has accepted for review CSL Behring's Biologics License Application (BLA) for its novel investigational recombinant factor VIII single-chain (rVIIISingleChain) for the treatment of haemophilia A.

28/07/2015

Competitive Advanced Manufacturing - Quite within Reach for Australia

Securing a globally competitive locally-based advanced manufacturing sector is quite within reach for Australia, according to CSL Limited, Australia's largest biotechnology company.

31/07/2015

Update on Novartis influenza vaccines acquisition

CSL Limited (ASX:CSL; USOTC: CSLLY) today announced that it has secured the necessary approvals required to proceed with the acquisition of the influenza vaccines business of Novartis and that it is working with Novartis to bring forward the close date for the transaction.

03/08/2015

CSL completes Novartis influenza vaccine business acquisition

CSL Limited (ASX:CSL; USOTC: CSLLY) today announced that it has now closed its transaction to acquire Novartis global influenza vaccine business for a cash consideration of US$275 million.

03/08/2015

Australia's Innovation System Could Deliver More

Australia's System of Innovation has the potential to deliver significantly more in terms of economic productivity, CSL told a Senate Inquiry in Melbourne today.

04/08/2015

CSL Supports New Medical Research Future Fund

Melbourne, Australia – CSL told the Senate Inquiry into the Medical Research Future Fund (MRFF) in Melbourne today that it was strongly supportive of the new fund and saw it as an acknowledgement of the significant economic benefits that Australia derives from investment in medical research.

12/08/2015

Strong Full Year Result

CSL Limited (ASX:CSL; USOTC:CSLLY) today announced a net profit after tax (NPAT) of US$1,379 million for the full year ended 30 June 2015, up 6% on a reported basis when compared to the prior comparable period (PCP).

07/09/2015

CSL standing firm on Enterprise Agreement Offer

Union demands for a pay rise of 11.5% over 3 years are not sustainable says CSL as it prepares to put its offer of a 9.75% wage increase to an employee vote for the second time.

09/10/2015

New CHF400 Million & USD100 Million US Private Placement

CSL today announced that on 8 October 2015 it has closed a new CHF400 million and USD100 million private placement in the US.

09/10/2015

CSL Names David Lamont as Chief Financial Officer

CSL today named Mr. David Lamont, an accomplished global financial leader with a diverse commercial background, as its Chief Financial Officer (CFO), effective 2 January 2016.

15/10/2015

CSL announces record A$1 billion share buyback

CSL today announced a new on-market share buyback of up to A$1 billion. The new buyback will be the largest ever undertaken by the company as part of its regular buyback program.

15/10/2015

CSL Welcomes New Lifetime Immunisation Register

CSL congratulates the Federal Government on the successful passage of legislation to establish an Australian Immunisation Register (AIR).

09/11/2015

CSL brands world's no. 2 influenza vaccine provider as Seqirus

Global biotherapeutics leader CSL Limited announced that its influenza vaccines business will begin operating under the brand Seqirus effective today, following the merger of the recently-acquired Novartis influenza business and its existing vaccines and pharmaceutical business bioCSL.

27/11/2015

CSL Salutes the Australian Science Media Centre

CSL congratulates the Australian Media Science Centre (AusSMC) on ten years of service to the Australian community.

10/12/2015

Research & Development Investor Briefing

CSL Limited (ASX:CSL; USOTC:CSLLY) conducted its annual research & development briefing for investors on Thursday 10 December 2015.